[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Stephen Cohen [@q_xvx_](/creator/twitter/q_xvx_) on x 7750 followers Created: 2025-07-18 13:21:35 UTC 📈 [Today's Stock Forecast] Stock Code: $DNTH Purchase Price: $18.12-19.31 Target Price: $25-35 Stop Loss Price: $XX Holding Period: 20-30 Days Positive Factors: Clinical Progress: DNTH103 (monoclonal antibody targeting C1s complement protein) is advancing in multiple clinical trials Financial Status: Cash and equivalents of $XXXXX million as of September 30, 2024, expected to support operations until the second half of 2027. Revenue in 2024 was $XXXX million (up XXXXXX% year-on-year), but net loss was $XXXXX million (up XXXX% year-on-year). Leadership Team: On March 5, John C. King was appointed as Chief Business Officer (who launched the first gMG complement inhibitor), and Sujay Kango joined the board of directors to enhance commercialization capabilities. On May 22, Dr. Simon Read (former CEO of Mariana Oncology) joined to strengthen research and development. Risk factors: Financial risks: R&D expenses of $XXXX million in 2024 (year-on-year increase), net loss of $XXXX million in Q1 2025 (EPS -$0.82, worse than last year's -$0.54), and the path to profitability is unclear. High volatility: The price has dropped from $XXXXX to $XXXXX this year, with a maximum drop of 58.54%, and the risk of short-term correction is high. Short pressure: XXXXX% of floating shares are shorted, with XXXX days of short coverage, and the bear market sentiment is significant, which may trigger further selling  XXXXX engagements  **Related Topics** [$dnth](/topic/$dnth) [Post Link](https://x.com/q_xvx_/status/1946198665162596598)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Stephen Cohen @q_xvx_ on x 7750 followers
Created: 2025-07-18 13:21:35 UTC
📈 [Today's Stock Forecast]
Stock Code: $DNTH Purchase Price: $18.12-19.31 Target Price: $25-35 Stop Loss Price: $XX Holding Period: 20-30 Days
Positive Factors:
Clinical Progress: DNTH103 (monoclonal antibody targeting C1s complement protein) is advancing in multiple clinical trials
Financial Status: Cash and equivalents of $XXXXX million as of September 30, 2024, expected to support operations until the second half of 2027. Revenue in 2024 was $XXXX million (up XXXXXX% year-on-year), but net loss was $XXXXX million (up XXXX% year-on-year).
Leadership Team: On March 5, John C. King was appointed as Chief Business Officer (who launched the first gMG complement inhibitor), and Sujay Kango joined the board of directors to enhance commercialization capabilities. On May 22, Dr. Simon Read (former CEO of Mariana Oncology) joined to strengthen research and development.
Risk factors:
Financial risks: R&D expenses of $XXXX million in 2024 (year-on-year increase), net loss of $XXXX million in Q1 2025 (EPS -$0.82, worse than last year's -$0.54), and the path to profitability is unclear.
High volatility: The price has dropped from $XXXXX to $XXXXX this year, with a maximum drop of 58.54%, and the risk of short-term correction is high.
Short pressure: XXXXX% of floating shares are shorted, with XXXX days of short coverage, and the bear market sentiment is significant, which may trigger further selling
XXXXX engagements
Related Topics $dnth